AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8258839 — intervention group
Group type: COMPARATOR
Intervention: Standard management at 37 degrees C (n = 22)
Number of subjects: 46
Study 3014925 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 16
Study 3014925 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 16
Study 30133467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (contextualised behavioural intervention strategies)
Number of subjects: 479
Study 30133467 — intervention group
Group type: COMPARATOR
Intervention: Control arm (general dietary information leaflets)
Number of subjects: 479
Study 26988650 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-fat yogurt consumption (quintiles Q1 to Q5)
Number of subjects: 4545
Study 26988650 — intervention group
Group type: COMPARATOR
Intervention: Total yogurt consumption
Number of subjects: 4545
Study 23869755 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS patients
Number of subjects: 58
Study 23869755 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 58
Study 22398313 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (6 fractions per week, 66-68 Gy in 33-34 fractions)
Number of subjects: 1476
Study 22398313 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (5 fractions per week, 66-68 Gy in 33-34 fractions)
Number of subjects: 1476
Study 22398313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Accelerated and Conventional radiotherapy)
Number of subjects: 1476
Study 20150531 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, cognitive-based and classical stress management exercises and a chat room
Number of subjects: 0
Study 20150531 — intervention group
Group type: COMPARATOR
Intervention: Static version of the program including health screening tool, diary and information about stress
Number of subjects: 0
Study 18313286 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil bolus 0.5 microg/kg before induction followed by a continuous infusion at 0.15 microg x kg(‐1)min(‐1) until peritoneal incision, then restarted after delivery
Number of subjects: 42
Study 18313286 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl after delivery
Number of subjects: 42
Study 15699241 — intervention group
Group type: COMPARATOR
Intervention: 15 g alcohol/d (one drink)
Number of subjects: 53
Study 15699241 — intervention group
Group type: COMPARATOR
Intervention: 30 g alcohol/d (2 drinks)
Number of subjects: 53
Study 12447291 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation guided by conventional monitoring (heart rate, blood pressure, oxygen saturation, electrocardiogram)
Number of subjects: 80
Study 12447291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation guided by electroencephalogram monitoring displayed online
Number of subjects: 80
Study 10050562 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine HCl (1,500 mg/day), chondroitin sulfate (1,200 mg/day), and manganese ascorbate (228 mg/day)
Number of subjects: 34
Study 8587273 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 627
Study 2200174 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of maintenance dose of CsA (group 1, n = 27)
Number of subjects: 51
Study 2200174 — intervention group
Group type: COMPARATOR
Intervention: Discontinue CsA (group 2, n = 24)
Number of subjects: 51
Study 90280 — intervention group
Group type: EXPERIMENTAL
Intervention: Various cancer treatments under study
Number of subjects: 0
Study 30483971 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (Suntalk website)
Number of subjects: 313
Study 30483971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 313
Study 27765643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic stratified care
Number of subjects: 688
Study 27765643 — intervention group
Group type: COMPARATOR
Intervention: Best current care
Number of subjects: 688
Study 26456905 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg) and elbasvir (50 mg) once daily for 12 weeks
Number of subjects: 224
Study 26456905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (deferred treatment group)
Number of subjects: 224
Study 26456905 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir and elbasvir (combined immediate treatment group and intensive pharmacokinetic population)
Number of subjects: 224
Study 26456905 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir and elbasvir (immediate treatment group)
Number of subjects: 224
Study 23252963 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg/d at bedtime)
Number of subjects: 69
Study 23252963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 23252963 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 69
Study 19926622 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d (group R, n = 20)
Number of subjects: 60
Study 19926622 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d plus fenofibrate 200 mg/d (group RF, n = 20)
Number of subjects: 60
Study 19926622 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d plus ezetimibe 10 mg/d (group RE, n = 20)
Number of subjects: 60
Study 19926622 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 18067188 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 69
Study 18067188 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the internal globus pallidus (GPi)
Number of subjects: 69
Study 17543201 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate and vitamin B12 supplementation
Number of subjects: 0
Study 12799508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccination
Number of subjects: 46074
Study 12799508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 46074
Study 11082471 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic status children
Number of subjects: 217
Study 11082471 — intervention group
Group type: COMPARATOR
Intervention: High socioeconomic status children
Number of subjects: 217
Study 11082471 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's cortisol levels
Number of subjects: 217
Study 8675426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen exposure
Number of subjects: 0
Study 8675426 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study 1508357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium naproxen 275 mg i.m. administered at the end of surgery and after 12 hours
Number of subjects: 40
Study 1508357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium naproxen 550 mg i.m. administered at the end of surgery and after 12 hours
Number of subjects: 40
Study 6379708 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise tolerance training (weekly attendance and daily home exercises)
Number of subjects: 24
Study 6379708 — intervention group
Group type: COMPARATOR
Intervention: Exercise at home only (control group)
Number of subjects: 24
Study 29715296 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltodextrin (IMD)
Number of subjects: 0
Study 26847229 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 41062
Study 26847229 — intervention group
Group type: COMPARATOR
Intervention: No decision support system (Control)
Number of subjects: 41062
Study 25617625 — intervention group
Group type: EXPERIMENTAL
Intervention: Rg1 (5 mg)
Number of subjects: 2
Study 25617625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 23432159 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fusidic acid (FA) use
Number of subjects: 185
Study 23432159 — intervention group
Group type: COMPARATOR
Intervention: No topical fusidic acid use
Number of subjects: 185
Study 23432159 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous use of topical FA
Number of subjects: 185
Study 21138714 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic warnings about drinking and driving
Number of subjects: 1215
Study 21138714 — intervention group
Group type: EXPERIMENTAL
Intervention: KYL BAC estimation cards
Number of subjects: 1215
Study 21138714 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives to moderate drinking
Number of subjects: 1215
Study 21138714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1215
Study 18442509 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat Well with CF (intervention)
Number of subjects: 68
Study 18442509 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 68
Study 16526986 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus androgen deprivation therapy (ADT)
Number of subjects: 0
Study 16526986 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus ADT prior to radical prostatectomy
Number of subjects: 0
Study 12714022 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 60 mg via buccal route
Number of subjects: 12
Study 12714022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10920581 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB photochallenge testing
Number of subjects: 36
Study 10920581 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA photochallenge testing
Number of subjects: 36
Study 10920581 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMX) usage
Number of subjects: 36
Study 8617190 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day of zinc as zinc sulfate)
Number of subjects: 50
Study 8617190 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study 1289175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg daily
Number of subjects: 142
Study 1289175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g daily
Number of subjects: 142
Study 1289175 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 142
Study 2982532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine stimulation
Number of subjects: 0
Study 2982532 — intervention group
Group type: COMPARATOR
Intervention: Sweat from patients with cystic fibrosis
Number of subjects: 0
Study 31102079 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster highlighting the futility of antibiotic treatment for colds
Number of subjects: 299
Study 31102079 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster highlighting the risk of adverse drug reactions from antibiotics
Number of subjects: 299
Study 31102079 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster highlighting the issue of antimicrobial resistance
Number of subjects: 299
Study 29298160 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative autologous stem-cell transplantation
Number of subjects: 75
Study 29298160 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 75
Study 27359129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive self-control tasks
Number of subjects: 174
Study 27359129 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral self-control tasks
Number of subjects: 174
Study 27359129 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 174
Study 27359129 — intervention group
Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 174
Study 24726247 — intervention group
Group type: COMPARATOR
Intervention: OPV0
Number of subjects: 511
Study 22152078 — intervention group
Group type: EXPERIMENTAL
Intervention: HI resistance training
Number of subjects: 46
Study 22152078 — intervention group
Group type: EXPERIMENTAL
Intervention: MI resistance training
Number of subjects: 46
Study 22152078 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-BFR resistance training
Number of subjects: 46
Study 22152078 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (C)
Number of subjects: 46
Study 20473861 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (SA) with prostate-specific antigen test every 4 years (cut-off 4.0 ng/ml)
Number of subjects: 80814
Study 20473861 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CA) with no interventions
Number of subjects: 80814
Study 20473861 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (SA)
Number of subjects: 80814
Study 20473861 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 80814
Study 18606932 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified maize-soy flour (likuni phala [LP])
Number of subjects: 182
Study 18606932 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of fortified spread (FS50)
Number of subjects: 182
Study 18606932 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of fortified spread (FS25)
Number of subjects: 182
Study 16669719 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program with olanzapine
Number of subjects: 48
Study 12816888 — intervention group
Group type: EXPERIMENTAL
Intervention: Autistic group
Number of subjects: 41
Study 10651837 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 12
Study 10651837 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 8692147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (10 mg) given via portal system for intestinal type
Number of subjects: 0
Study 8692147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (10 mg) given in peritoneal cavity for diffuse type
Number of subjects: 0
Study 2062515 — intervention group
Group type: EXPERIMENTAL
Intervention: Early photocoagulation
Number of subjects: 0
Study 2062515 — intervention group
Group type: COMPARATOR
Intervention: Deferral of photocoagulation (control)
Number of subjects: 0
Study 6851968 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of norethisterone
Number of subjects: 9
Study 6851968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of norethisterone
Number of subjects: 9
Study 6851968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30784422 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention (Living Better)
Number of subjects: 106
Study 30784422 — intervention group
Group type: COMPARATOR
Intervention: Usual medical treatment (Control Group)
Number of subjects: 106
Study 29241359 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 636
Study 29241359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 636
Study 29241359 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 636
Study 29241359 — intervention group
Group type: EXPERIMENTAL
Intervention: GG genotype (validation sample)
Number of subjects: 636
Study 26925867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid responsiveness protocol using Non‐Invasive Cardiac Output Monitor (NICOM)
Number of subjects: 64
Study 26925867 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 64
Study 23892504 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2 % lidocaine cream
Number of subjects: 64
Study 23892504 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 64
Study 22270141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (HBB) intravenous (i.v.)
Number of subjects: 6
Study 22270141 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (GLU) intravenous (i.v.)
Number of subjects: 6
Study 22270141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (HBB) intramuscular (i.m.)
Number of subjects: 6
Study 22270141 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (GLU) intramuscular (i.m.)
Number of subjects: 6
Study 22270141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined scheme (i.v. GLU + i.m. HBB)
Number of subjects: 6
Study 19844176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) 40 mg once daily
Number of subjects: 156
Study 19844176 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5000 IU twice daily
Number of subjects: 156
Study 17077344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise for 90 min (67% VO2 peak)
Number of subjects: 38
Study 17077344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise for 20 min (80% VO2 peak)
Number of subjects: 38
Study 17077344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise for 2 min (110% of peak work rate)
Number of subjects: 38
Study 17077344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise for 30 s (maximal sprint)
Number of subjects: 38
Study 16222402 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg for 5 days and 0.07 g/kg thereafter) with resistance training
Number of subjects: 29
Study 16222402 — intervention group
Group type: COMPARATOR
Intervention: Placebo with resistance training
Number of subjects: 29
Study 16222402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (creatine and placebo)
Number of subjects: 29
Study 12174698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial Asthma (BA)
Number of subjects: 1068
Study 12174698 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Obstructive Pulmonary Disease (COPD)
Number of subjects: 1068
Study 12174698 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Acquired Pneumonia (CAP)
Number of subjects: 1068
Study 10208784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 1276
Study 10208784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1276
Study 10208784 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1276
Study 8703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide turbuhaler (200 micrograms/dose), two inhalations, twice daily for eight weeks
Number of subjects: 20
Study 8703248 — intervention group
Group type: COMPARATOR
Intervention: Placebo turbuhaler
Number of subjects: 20
Study 8703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide turbuhaler (200 micrograms/dose)
Number of subjects: 20
Study 2192717 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate retard plus colestyramine (24 g/d)
Number of subjects: 47
Study 2192717 — intervention group
Group type: COMPARATOR
Intervention: bezafibrate (400 mg/d)
Number of subjects: 47
Study 2192717 — intervention group
Group type: COMPARATOR
Intervention: colestyramine plus placebo
Number of subjects: 47
Study 380773 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 27
Study 380773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31599851 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale for pain intensity descriptors
Number of subjects: 248
Study 31599851 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation order of descriptors
Number of subjects: 248
Study 30711430 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education by simulation
Number of subjects: 26
Study 30711430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 27821673 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability training
Number of subjects: 32
Study 27821673 — intervention group
Group type: COMPARATOR
Intervention: Conventional programs
Number of subjects: 32
Study 25873067 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Control Treatment
Number of subjects: 216
Study 25873067 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy
Number of subjects: 216
Study 23617250 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 12
Study 23617250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21896134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-Lys-Glu-Lys (PKEK)
Number of subjects: 0
Study 21896134 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 19890182 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging technologies in spine care
Number of subjects: 0
Study 19890182 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical therapies models (e.g., quality-adjusted life years)
Number of subjects: 0
Study 19890182 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative efforts
Number of subjects: 0
Study 17048094 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS teaching (15 hours over 4-5 weeks)
Number of subjects: 41
Study 17048094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PECS teaching)
Number of subjects: 41
Study 15353006 — intervention group
Group type: EXPERIMENTAL
Intervention: Active interventions
Number of subjects: 3202
Study 15353006 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 3202
Study 15353006 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3202
Study 11557913 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g activated charcoal as a suspension
Number of subjects: 9
Study 11557913 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g activated charcoal as a suspension followed by whole-bowel irrigation with polyethylene glycol (PEG) electrolyte lavage solution
Number of subjects: 9
Study 11557913 — intervention group
Group type: COMPARATOR
Intervention: 200 mL water (control)
Number of subjects: 9
Study 9589857 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphism of the angiotensinogen gene in patients with coronary heart disease
Number of subjects: 0
Study 9589857 — intervention group
Group type: COMPARATOR
Intervention: Random sample from the Moscow population
Number of subjects: 0
Study 8146409 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg salbutamol CR twice daily
Number of subjects: 25
Study 8146409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25